Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Ovarian Neoplasms 5Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Retinoblastoma 2Neoplasms 2Neoplasm Metastasis 2Head and Neck Neoplasms 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous-Cell Lung Cancer 1Sjogren's Syndrome 1Scleroderma, Systemic 1Retinal Neoplasms 1Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) 1Resectable Non-small Cell Lung Cancer 1Resectable Lung Non-Small Cell Carcinoma 1Recurrence 1Psoriasis 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Cancer Recurrent 1Oropharyngeal Neoplasms 1Nonsquamous Non-small Cell Lung Cancer 1Non-Squamous Non-Small Cell Lung Cancer 1NSCLC 1Multiple Sclerosis 1Melanoma 1

Interventions

Carboplatin 69Paclitaxel 47Radiotherapy 44Pemetrexed 42Cisplatin 41Bevacizumab 36Gemcitabine 27Docetaxel 27Erlotinib Hydrochloride 23Gefitinib 18pembrolizumab 14Taxes 13Vinorelbine 10Cetuximab 10Radiation 8Nivolumab 8Magnetic Resonance Spectroscopy 8Radiosurgery 7Platinum 7Etoposide 7Surgical Procedures, Operative 6Radiotherapy, Conformal 6ceritinib 5capmatinib 5aflutinib 5Specimen Handling 5Neoadjuvant Therapy 5Mastectomy, Segmental 5Cyclophosphamide 5tislelizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Adenocarcinoma of Lung × Platinum Compounds × Clear all
NCT05675033 2023-01-09

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Fujian Cancer Hospital

Phase 2 Unknown
50 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡